We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $65.95, marking a -0.18% move from the previous day. This move lagged the S&P 500's daily gain of 1.06%. Meanwhile, the Dow gained 1.05%, and the Nasdaq, a tech-heavy index, added 0.4%.
Prior to today's trading, shares of the pharmaceutical had lost 1.34% over the past month. This has was narrower than the Medical sector's loss of 3.76% and the S&P 500's loss of 8.3% in that time.
Astrazeneca will be looking to display strength as it nears its next earnings release, which is expected to be July 29, 2022. The company is expected to report EPS of $0.86, up 91.11% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $10.46 billion, up 27.26% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.30 per share and revenue of $43.59 billion. These totals would mark changes of +24.53% and +16.49%, respectively, from last year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Astrazeneca is currently a Zacks Rank #3 (Hold).
In terms of valuation, Astrazeneca is currently trading at a Forward P/E ratio of 20.02. Its industry sports an average Forward P/E of 13.12, so we one might conclude that Astrazeneca is trading at a premium comparatively.
Meanwhile, AZN's PEG ratio is currently 1.23. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 149, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AZN in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $65.95, marking a -0.18% move from the previous day. This move lagged the S&P 500's daily gain of 1.06%. Meanwhile, the Dow gained 1.05%, and the Nasdaq, a tech-heavy index, added 0.4%.
Prior to today's trading, shares of the pharmaceutical had lost 1.34% over the past month. This has was narrower than the Medical sector's loss of 3.76% and the S&P 500's loss of 8.3% in that time.
Astrazeneca will be looking to display strength as it nears its next earnings release, which is expected to be July 29, 2022. The company is expected to report EPS of $0.86, up 91.11% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $10.46 billion, up 27.26% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.30 per share and revenue of $43.59 billion. These totals would mark changes of +24.53% and +16.49%, respectively, from last year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Astrazeneca is currently a Zacks Rank #3 (Hold).
In terms of valuation, Astrazeneca is currently trading at a Forward P/E ratio of 20.02. Its industry sports an average Forward P/E of 13.12, so we one might conclude that Astrazeneca is trading at a premium comparatively.
Meanwhile, AZN's PEG ratio is currently 1.23. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 149, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AZN in the coming trading sessions, be sure to utilize Zacks.com.